Sofosbuvir declatasvir

The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in. Indicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection

2024-03-28
    Max vigor natural energy booster
  1. Methods Three clinical trials comparing sofosbuvir/daclatasvir
  2. Patients with cirrhosis were treated for 24 weeks
  3. Expert Rev Gastroenterol
  4. This trial aims
  5. It is taken by mouth
  6. 021
  7. Drug information provided by: Merative, Micromedex® US Brand Name